在福岛年轻甲状腺癌患者中鉴定出三种新型融合癌基因:SQSTM1/NTRK3、AFAP1L2/RET 和 PPFIBP2/RET
研究对福岛甲状腺超声筛查发现的63例儿童及青少年甲状腺乳头状癌术后标本中9例已知常见癌基因阴性者进行分析,通过定量实时逆转录聚合酶链反应筛查及5' cDNA末端快速扩增,鉴定出两种已知融合(STRN/ALK、TPR/NTRK1)和三种新型融合(SQSTM1/NTRK3、AFAP1L2/RET、PPFIBP2/RET),功能分析证实三种嵌合基因可通过激活丝裂原活化蛋白激酶(MAPK)发挥转化能力。作者认为该年龄组已知癌基因阴性病例中可能存在罕见融合,此类重排可在甲状腺癌发生中起重要作用。
要点
- 在9例已知癌基因阴性的儿童及青少年PTC中,5例疑似存在融合,其中鉴定出3种新型融合癌基因。
- 三种新型融合基因为SQSTM1/NTRK3、AFAP1L2/RET和PPFIBP2/RET,功能分析证实其转化能力。
- 作者认为该年龄组已知癌基因阴性病例中可能存在罕见融合,此类重排可在甲状腺癌发生中起重要作用。
核心结论
- 在福岛年轻PTC患者中鉴定出三种新型融合癌基因,提示该年龄组已知癌基因阴性病例中可能存在罕见融合,此类重排可在甲状腺癌发生中起重要作用。
研究设计与样本
- 研究分析了福岛甲状腺超声筛查项目发现的63例儿童及青少年PTC术后标本中9例无常见已知癌基因(BRAFV600E、RAS、RET/PTC1、RET/PTC3、ETV6/NTRK3)的样本,采用定量实时逆转录聚合酶链反应比较ALK、NTRK1、NTRK3和RET的细胞外域与激酶域转录表达以筛查新型融合基因。
主要发现
- 9例样本中5例疑似存在融合,经5' cDNA末端快速扩增鉴定出两种已知融合癌基因STRN/ALK和TPR/NTRK1,以及三种新型融合SQSTM1/NTRK3、AFAP1L2/RET和PPFIBP2/RET。
- 对三种嵌合基因的功能分析证实其通过激活丝裂原活化蛋白激酶(MAPK)具有转化能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The BRAFV600E mutation is the most frequent genetic abnormality in adult papillary thyroid carcinomas (PTCs). On the other hand, various chromosomal rearrangements are more prevalent in childhood and adolescent PTCs. The aim of the present study was to identify novel rearrangements in PTCs from young patients. METHODS: Among 63 postoperative specimens of childhood and adolescent PTCs, which had been discovered by the thyroid ultrasound screening program in Fukushima, nine samples without prevalent known oncogenes, BRAFV600E, RAS, RET/PTC1, RET/PTC3, and ETV6/NTRK3, were analyzed in the current study by quantitative real-time reverse transcription polymerase chain reaction to screen for novel fusion genes by comparing transcript expression between extracellular and kinase domains of ALK, NTRK1, NTRK3, and RET. RESULTS: Of the above nine samples, five samples were suspected to harbor a fusion, and using subsequent 5' rapid amplification of cDNA end (RACE), two already reported fusion oncogenes, STRN/ALK and TPR/NTRK1, and three novel fusions, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, were identified. Functional analyses of these three chimeric genes were performed, and their transforming abilities were confirmed through the activation of mitogen-activated protein kinase (MAPK). CONCLUSIONS: Three novel fusion oncogenes have been identified in young PTC patients in Fukushima, suggesting that rare fusions may be present among the cases negative for known oncogenes in this age group and that such rearrangements can play a significant role in thyroid carcinogenesis.
引用
- Iyama K, Matsuse M, Mitsutake N, et al. Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in Thyroid Cancers of Young Patients in Fukushima. Thyroid. 2017. PMID: 28351223. doi:10.1089/thy.2016.0673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。